“Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients ” (2019) Journal of Analytical Oncology, 8, pp. 71–76. doi:10.30683/1927-7229.2019.08.10.